Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/bBFDy5dNZKY/269505.php
Sunday, 1 December 2013
Velphoro (PA21) receives US FDA approval for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis
Velphoro® (sucroferric oxyhydroxide) has received US Food and Drug Administration (FDA) approval for the control of serum phosphorus levels in patients with Chronic Kidney Disease (CKD) on dialysis. Velphoro® will be launched in the US by Fresenius Medical Care North America in 2014.Velphoro® (previously known as PA21) is an iron-based, calcium-free, chewable phosphate binder. US approval was based on a pivotal Phase III study, which met its primary and secondary endpoints.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment